Colorectal Cancer

Recent research found that patients under 50 were less likely to have a treatment-determining biomarker than their older counterparts.

This year’s survey is expanded to better learn about the experience of caregivers, with a selection of questions specifically for them. The Alliance asks that just one caregiver per patient fill out the survey.

Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.

By getting their tumor genetically tested, a patient may find out that they are eligible for certain treatment options.

It was the drop heard 'round the colorectal cancer world.

After losing her husband and sister to cancer, journalist Katie Couric became an advocate for collaborative efforts to improve prevention and treatment.

The science behind immunotherapy and gastrointestinal cancers is not quite perfected yet, but one subset of patients is seeing remarkable results.

Despite improved outcomes, the researchers also found that side effects with checkpoint inhibition often affected the dermatologic, gastrointestinal, pulmonary, renal, endocrine and hepatic systems in patients.

CURE spoke with a childhood development specialist and colorectal cancer survivor to offer firsthand advice and tips on how to discuss a cancer diagnosis with children of any age.

Survivors of colorectal cancer have a greater chance of hypertension (high blood pressure) and worse blood pressure control compared with people who do not have cancer, according to study findings.

The National Colorectal Cancer Roundtable has created a special toolkit to help physicians successfully determine and evaluate family history to detect colorectal cancer at an earlier age.

“Young people, in general, think they are invincible. I certainly did.” Said Stacy Hurt, an early-age onset rectal cancer survivor.

If patients with colon cancer follow the previously-issued American Cancer Society guidelines on nutrition and physical activity, they can improve outcomes in to survivorship.

With immunotherapy continuing to command headlines in the world of oncology, it’s no surprise that patients with a variety of cancers wonder whether the strategy might help them address and overcome their illnesses.

Funded posthumously by a "Jeopardy!" winner, an immunotherapy research project is under way.

The combination induced a 31 percent disease control rate (DCR) in patients with heavily-pretreated metastatic colorectal cancer (mCRC).

The understanding of genetic mutations, like tumors that are microsatellite instability-high (MSI-H), and the therapies that go along with them is transforming the world of colorectal cancer, according to John Marshall, M.D.

Immunotherapy may play a growing role in treating gastrointestinal cancers categorized as MSI-high.

Laparoscopy proves safer than open surgery and costs less than robotic resection for colorectal cancer.

Next-generation sequencing could help identify MSI-H status in patients, which could have important implications for treatment plans.

A nasty stomach virus might have saved this survivor from colon cancer.

Colorectal cancer expert John Marshall, M.D., shares his feelings about the month of March, which is Colorectal Cancer Awareness month.

Tony Beasley has spent years in the MLB as a third-base coach for the Texas Rangers. Little did he know his competitive nature and critical thinking would come in to play in his fight against stage 2 colorectal cancer. Since, Beasley has teamed up with Fight CRC as part of their One Million Strong Campaign to help others do one thing: Develop a mentality to fight.

CURE spoke with Scott Paulson, M.D., medical oncologist with Texas Oncology, an affiliate of The US Oncology Network, to break down exactly what MSI-H status is, and the effects it may have on certain malignancies.

The identification of microsatellite status, tumor mutational burden and protein expression in colorectal cancer (CRC) tumors may lead to better outcomes in a subgroup of patients.

Patients with microsatellite instability-high (MSI-H) colorectal cancer may undergo a distinct pattern of clonal evolution, which in turn, would impact the use of targeted and immunologic therapies in these patients, according to study results presented at the 2018 Gastrointestinal Cancer Symposium.

Patients previously treated for DNA mismatch repair (MMR)-deficient/microsatellite instability-high (MSI-H) metastatic colorectal cancer may have a new effective treatment option.

Texas Rangers third-base coach Tony Beasley teams up with Fight CRC, sharing his journey into survivorship and inspiring others in their fight against cancer.